Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 20/100

Failure Rate

9.1%

2 terminated/withdrawn out of 22 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

32%

7 trials in Phase 3/4

Results Transparency

75%

9 of 12 completed trials have results

Key Signals

2 recruiting9 with results

Enrollment Performance

Analytics

Phase 2

7(36.8%)

Phase 3

7(36.8%)

Phase 1

3(15.8%)

Early Phase 1

2(10.5%)

19Total

Phase 2(7)

Phase 3(7)

Phase 1(3)

Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT03970447Phase 2Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Role: collaborator

NCT07125261Phase 1Active Not Recruiting

BHV-7000 Responsive Neurostimulation System (RNS) Study

Role: collaborator

NCT04708834Phase 3Terminated

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Role: lead

NCT05337553Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Role: lead

NCT03299166Phase 2Completed

Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder

Role: lead

NCT06034886Unknown

Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Role: lead

NCT04641143Phase 3Completed

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Role: lead

NCT03701399Phase 3Active Not Recruiting

Troriluzole in Adult Participants With Spinocerebellar Ataxia

Role: lead

NCT02960893Phase 2Completed

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

Role: lead

NCT06552260Early Phase 1Recruiting

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Role: collaborator

NCT04693351Phase 3Completed

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Role: lead

NCT04634435Phase 1Completed

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Role: lead

NCT03829241Phase 3Completed

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

Role: lead

NCT04899921Phase 2Terminated

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Role: collaborator

NCT03605667Phase 2Completed

Study of BHV-4157 in Alzheimer's Disease

Role: lead

NCT03952806Phase 3Completed

Study of BHV-3241 in Participants With Multiple System Atrophy

Role: lead

NCT04436510Phase 2Completed

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Role: collaborator

NCT03520517Phase 1Completed

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

Role: lead

NCT05086094Unknown

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Role: lead

NCT04616456Early Phase 1Completed

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Role: collaborator